Energenesis Biomedical Co (TPE:6657) FFO per Share

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TPE:6657 Energenesis Biomedical Co Ltd TPE:6657
64 GF Score
Price NT$34.00
GF Value NT$51.54
Valuation Possible Value Trap
! 3 Warning Signs
View Full Analysis

What is Energenesis Biomedical Co FFO per Share?

FFO per Share only applies to REITs.

TPE:6657
64GF Score
Energenesis Biomedical Co Ltd TPE:6657
FFO per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Energenesis Biomedical Co (TPE:6657) Overvalued in 2026?

Based on GuruFocus' analysis, Energenesis Biomedical Co stock appears to be undervalued. The current stock price of NT$34.00 is trading 34% below its estimated GF Value™ of NT$51.54. GuruFocus considers Energenesis Biomedical Co to be Possible Value Trap.

Key valuation signals for TPE:6657:

  • FFO per Share:
  • GF Value™: NT$51.54 vs. price of NT$34.00 (34% below fair value)
  • GF Score™: 64/100 with 3 warning signs

No single metric tells the full story. See the TPE:6657 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Energenesis Biomedical Co Business Description

Address No. 21, Lane 583, Ruiguang Road, 6th Floor -3, Neihu District, Taipei, TWN, 11492
Energenesis Biomedical Co Ltd is a biomedicine company. The company is engaged in businesses related to biological experimentation and analysis, as well as new drugs development. The company uses its ENERGI drug development platform to activate AMP-activated protein kinase (AMPK), a key enzyme in cell energy regulation, as a means of developing disease treatments. The product pipeline of the company consists of ENERGI-F703, a diabetic foot ulcers treatment gel; ENERGI-F701, a product developed for male hair loss; ENERGI-F704, an inflammatory bowel disease treatment; and ENERGI-F711, a burn cream,F708, Asthama treatment, and others.
64GF Score

Get the complete analysis for TPE:6657

FFO per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$34.00
Price
NT$51.54
GF Value